You just read:

Roche selects Vivonoetics to provide advanced respiratory assessment for the FIREFISH Phase II multicenter clinical trial in infants with Spinal Muscular Atrophy Type 1.

News provided by

Vivonoetics

24 Jan, 2017, 13:45 ET